JP2004528379A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004528379A5 JP2004528379A5 JP2002587431A JP2002587431A JP2004528379A5 JP 2004528379 A5 JP2004528379 A5 JP 2004528379A5 JP 2002587431 A JP2002587431 A JP 2002587431A JP 2002587431 A JP2002587431 A JP 2002587431A JP 2004528379 A5 JP2004528379 A5 JP 2004528379A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- restenosis
- stent
- blood vessel
- arthritis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004204 blood vessel Anatomy 0.000 description 5
- 208000037803 restenosis Diseases 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000037259 Amyloid Plaque Diseases 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 201000009273 Endometriosis Diseases 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- 206010018364 Glomerulonephritis Diseases 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 description 2
- 208000022873 Ocular disease Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 206010038563 Reocclusion Diseases 0.000 description 2
- 208000034841 Thrombotic Microangiopathies Diseases 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 239000002473 artificial blood Substances 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 208000010247 contact dermatitis Diseases 0.000 description 2
- 208000033679 diabetic kidney disease Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 230000001434 glomerular Effects 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 230000001861 immunosuppressant effect Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 201000003142 neovascular glaucoma Diseases 0.000 description 2
- 201000009925 nephrosclerosis Diseases 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 208000003120 Angiofibroma Diseases 0.000 description 1
- 206010063209 Chronic allograft nephropathy Diseases 0.000 description 1
- 208000022461 Glomerular disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2001123574 DE10123574A1 (de) | 2001-05-08 | 2001-05-08 | Selektive Anthranylamid-Derivate als VEGFR II Inhibitoren |
| DE2001125294 DE10125294A1 (de) | 2001-05-15 | 2001-05-15 | Selektive Anthranylamid-Derivate als VEGFR-2 und VEGFR-3 Inhibitoren |
| DE2001164590 DE10164590A1 (de) | 2001-12-21 | 2001-12-21 | Anthranylamidpyridinamide als VEGFR-2 und VEGFR-3 Inhibitoren |
| PCT/EP2002/004924 WO2002090352A2 (de) | 2001-05-08 | 2002-05-03 | Selektive anthranylamidpyridinamide als vegfr-2 und vegfr-3 inhibitoren |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004528379A JP2004528379A (ja) | 2004-09-16 |
| JP2004528379A5 true JP2004528379A5 (enExample) | 2009-06-18 |
Family
ID=27214428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002587431A Pending JP2004528379A (ja) | 2001-05-08 | 2002-05-03 | Ｖｅｇｆｒ−２およびｖｅｇｆｒ−３インヒビターとしての選択的アントラニルアミドピリジンアミド |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20040254185A1 (enExample) |
| EP (1) | EP1392680B1 (enExample) |
| JP (1) | JP2004528379A (enExample) |
| KR (1) | KR20030094395A (enExample) |
| CN (1) | CN1518546A (enExample) |
| BR (1) | BR0209485A (enExample) |
| CA (1) | CA2453223A1 (enExample) |
| DE (1) | DE50213703D1 (enExample) |
| IL (1) | IL158783A0 (enExample) |
| MX (1) | MXPA03010099A (enExample) |
| NO (1) | NO20034957D0 (enExample) |
| PE (1) | PE20021092A1 (enExample) |
| PL (1) | PL364478A1 (enExample) |
| WO (1) | WO2002090352A2 (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10023486C1 (de) * | 2000-05-09 | 2002-03-14 | Schering Ag | Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel |
| DE10023484A1 (de) * | 2000-05-09 | 2001-11-22 | Schering Ag | Anthranylamide und deren Verwendung als Arzneimittel |
| US7105682B2 (en) | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
| US20030134836A1 (en) * | 2001-01-12 | 2003-07-17 | Amgen Inc. | Substituted arylamine derivatives and methods of use |
| US6995162B2 (en) * | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US6878714B2 (en) * | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US7102009B2 (en) | 2001-01-12 | 2006-09-05 | Amgen Inc. | Substituted amine derivatives and methods of use |
| US7307088B2 (en) * | 2002-07-09 | 2007-12-11 | Amgen Inc. | Substituted anthranilic amide derivatives and methods of use |
| US7615565B2 (en) * | 2002-07-31 | 2009-11-10 | Bayer Schering Pharma Aktiengesellschaft | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines |
| WO2004013102A1 (de) * | 2002-07-31 | 2004-02-12 | Schering Aktiengesellschaft | Vegfr-2 und vegfr-3 inhibitorische anthranylamidpyrimidene |
| GB0229022D0 (en) * | 2002-12-12 | 2003-01-15 | Novartis Ag | Organic Compounds |
| EP1628661A2 (en) * | 2003-06-05 | 2006-03-01 | Vertex Pharmaceuticals Incorporated | Modulators of vr1 receptor |
| DE10327719A1 (de) * | 2003-06-13 | 2005-01-20 | Schering Ag | VEGFR-2 und VEGFR-3 Inhibitorische Anthranylamidpyridone |
| US7202260B2 (en) * | 2003-06-13 | 2007-04-10 | Schering Ag | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones |
| US7129252B2 (en) * | 2003-06-16 | 2006-10-31 | Guoqing P Chen | Six membered amino-amide derivatives an angiogenisis inhibitors |
| UA89035C2 (ru) | 2003-12-03 | 2009-12-25 | Лео Фарма А/С | Эфиры гидроксамовых кислот и их фармацевтическое применение |
| DE102004009238A1 (de) * | 2004-02-26 | 2005-09-08 | Merck Patent Gmbh | Arylamid-Derivate |
| CN1660811A (zh) * | 2004-02-27 | 2005-08-31 | 中国科学院上海药物研究所 | 1，4－二取代苯类化合物及其制备方法和用途 |
| US7550499B2 (en) | 2004-05-12 | 2009-06-23 | Bristol-Myers Squibb Company | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| EP1655295A1 (en) * | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
| EP1657241A1 (en) * | 2004-11-03 | 2006-05-17 | Schering Aktiengesellschaft | Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
| EP1655297A1 (en) * | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
| US7906533B2 (en) | 2004-11-03 | 2011-03-15 | Bayer Schering Pharma Ag | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
| KR20060071812A (ko) * | 2004-12-22 | 2006-06-27 | 주식회사 엘지생명과학 | 신규한 3-(2-아미노-6-피리디닐)-4-히드록시페닐 아민유도체 |
| WO2006070878A1 (ja) * | 2004-12-28 | 2006-07-06 | Astellas Pharma Inc. | カルボン酸誘導体またはその塩 |
| WO2006078621A2 (en) | 2005-01-19 | 2006-07-27 | Bristol-Myers Squibb Company | 2-phenoxy-n- (1, 3 , 4-thiadizol-2-yl) pyridin-3-amine derivatives and related compounds as p2y1 receptor inhibitors for the treatment of thromboembolic disorders |
| JP4585978B2 (ja) * | 2005-03-03 | 2010-11-24 | 参天製薬株式会社 | キノリルアルキルチオ基を有する新規環式化合物 |
| DE602006017694D1 (de) | 2005-06-27 | 2010-12-02 | Bristol Myers Squibb Co | C-verknüpfte zyklische antagonisten des p2y1-rezeptors mit eignung bei der behandlung thrombotischer leiden |
| TW200726764A (en) | 2005-06-27 | 2007-07-16 | Bristol Myers Squibb Co | N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| WO2007002634A1 (en) * | 2005-06-27 | 2007-01-04 | Bristol-Myers Squibb Company | Carbocycle and heterocycle antagonists of p2y1 receptor useful in the treatment of thrombotic conditions |
| ATE502924T1 (de) | 2005-06-27 | 2011-04-15 | Bristol Myers Squibb Co | Lineare harnstoffmimetika-antagonisten des p2y1- rezeptors zur behandlung von thromboseleiden |
| US8247556B2 (en) | 2005-10-21 | 2012-08-21 | Amgen Inc. | Method for preparing 6-substituted-7-aza-indoles |
| CA2629964A1 (en) * | 2005-11-30 | 2007-06-07 | Astellas Pharma Inc. | 2-aminobenzamide derivative |
| US7960569B2 (en) | 2006-10-17 | 2011-06-14 | Bristol-Myers Squibb Company | Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| PE20081636A1 (es) * | 2007-01-26 | 2009-01-10 | Smithkline Beecham Corp | Inhibidores de antranilamida para aurora quinasa |
| FR2917413B1 (fr) | 2007-06-13 | 2009-08-21 | Sanofi Aventis Sa | Derives de 7-alkynyl-1,8-naphthyridones, leur preparation et leur application en therapeutique |
| RU2522444C2 (ru) | 2008-08-27 | 2014-07-10 | Лео Фарма А/С | Производные пиридина в качестве ингибиторов рецепторов фактора роста эндотелия сосудов 2 подтипа (vegfr-2) и протеинтирозинкиназы |
| US9340555B2 (en) | 2009-09-03 | 2016-05-17 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
| AU2010289353B2 (en) * | 2009-09-03 | 2016-12-08 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
| KR101524923B1 (ko) * | 2013-08-02 | 2015-06-01 | 가톨릭대학교 산학협력단 | ＩＦＮ－γ의 발현을 증가시키는 ＶＥＧＦＲ－３ 억제제를 유효성분으로 포함하는 급성골수성백혈병 치료용 약학적 조성물 |
| CN104163794A (zh) * | 2013-10-17 | 2014-11-26 | 中国药科大学 | 2-氨基芳环类血管内皮生长因子受体(vegfr)抑制剂及其制备方法和用途 |
| CN106496107A (zh) * | 2016-08-31 | 2017-03-15 | 浙江永宁药业股份有限公司 | Vegfr‑2抑制剂及其制备方法 |
| CN108467360B (zh) * | 2018-06-22 | 2021-04-30 | 江苏美迪克化学品有限公司 | 一种阿帕替尼的制备方法及其中间体 |
| US20210179543A1 (en) * | 2018-08-13 | 2021-06-17 | Western University Of Health Sciences | Calpain-2 selective inhibitor compounds for treatment of glaucoma |
| KR102371269B1 (ko) * | 2020-03-11 | 2022-03-07 | 연세대학교 산학협력단 | VEGFR-3 발현 조절을 통한 mTOR 관련 질환의 예방 또는 치료 방법 |
| CN117603175B (zh) * | 2023-11-27 | 2024-08-06 | 南开大学 | 一种苯并吡喃结构的查尔酮类衍生物及其制备方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5716993A (en) * | 1993-12-27 | 1998-02-10 | Eisai Co., Ltd. | Anthranilic acid derivatives |
| GB9824579D0 (en) * | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
| UA71587C2 (uk) * | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
| GB0001930D0 (en) * | 2000-01-27 | 2000-03-22 | Novartis Ag | Organic compounds |
| DE10023492A1 (de) * | 2000-05-09 | 2001-11-22 | Schering Ag | Aza- und Polyazanthranylamide und deren Verwendung als Arzneimittel |
| JP4343681B2 (ja) * | 2001-05-08 | 2009-10-14 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | シアノアントラニルアミド誘導体およびそれらの薬剤としての使用 |
| US7615565B2 (en) * | 2002-07-31 | 2009-11-10 | Bayer Schering Pharma Aktiengesellschaft | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines |
-
2002
- 2002-05-03 WO PCT/EP2002/004924 patent/WO2002090352A2/de not_active Ceased
- 2002-05-03 CN CNA028095804A patent/CN1518546A/zh active Pending
- 2002-05-03 PL PL02364478A patent/PL364478A1/xx unknown
- 2002-05-03 DE DE50213703T patent/DE50213703D1/de not_active Expired - Fee Related
- 2002-05-03 BR BR0209485-1A patent/BR0209485A/pt not_active IP Right Cessation
- 2002-05-03 CA CA002453223A patent/CA2453223A1/en not_active Abandoned
- 2002-05-03 MX MXPA03010099A patent/MXPA03010099A/es active IP Right Grant
- 2002-05-03 US US10/477,119 patent/US20040254185A1/en not_active Abandoned
- 2002-05-03 JP JP2002587431A patent/JP2004528379A/ja active Pending
- 2002-05-03 EP EP02735333A patent/EP1392680B1/de not_active Expired - Lifetime
- 2002-05-03 IL IL15878302A patent/IL158783A0/xx unknown
- 2002-05-03 KR KR10-2003-7014539A patent/KR20030094395A/ko not_active Ceased
- 2002-05-08 PE PE2002000384A patent/PE20021092A1/es not_active Application Discontinuation
-
2003
- 2003-11-07 NO NO20034957A patent/NO20034957D0/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004528379A5 (enExample) | ||
| JP6114274B2 (ja) | マグネシウム合金を含む吸収性ステント | |
| JP2006502112A5 (enExample) | ||
| BR0313122A (pt) | Antranilamidopiridinas inibidoras de vegfr-2 e vegfr-3 | |
| CA3039203A1 (en) | Compounds, devices, and uses thereof | |
| WO2007133520A3 (en) | Stent coating comprising titanium oxide or iridium oxide and a therapeutic agent | |
| CA2597067A1 (en) | Use of an scd-1 inhibitor to reduce adverse weight gain arising from drug therapy | |
| WO2006034315A3 (en) | Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes | |
| JP2012532131A5 (enExample) | ||
| JP2004531473A5 (enExample) | ||
| JP2009523133A (ja) | 再狭窄病変治療に有用なナノ粒子含有の薬化合物類 | |
| SG170101A1 (en) | 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial. | |
| WO2003009777A3 (en) | Delivery of therapeutic capable agents | |
| DE69940444D1 (de) | Verabreichung von Resveratrol zur Vorbeugung oder Behandlung von Restenose nach coronaren Eingriffen | |
| JP2024540839A5 (enExample) | ||
| WO2008062446A3 (en) | An extended release composition of levetiracetam, which exhibits no adverse food effect | |
| JP2017518360A5 (enExample) | ||
| JP2005539049A5 (enExample) | ||
| JP2017218449A5 (enExample) | ||
| MX2009002260A (es) | Cateter o desviacion implantable que permite el suministro gradual de agentes terapeuticos. | |
| CA3047448A1 (en) | Use of chymase inhibitors for the treatment of endometriosis, postoperative fibrosis and disorders that are characterized by fibrosis | |
| JP2005501060A (ja) | 硫黄含有有機硝酸化合物の使用法 | |
| RU2009127776A (ru) | Профилактическое или терапевтическое средство от алопеции | |
| RU2008102249A (ru) | Профилактический или терапевтичесский агент для корнеального /конъюнктивального заболевания | |
| WO1998042327B1 (en) | Vascular remodeling agent |